News & Info


Page 3 of 2712345...1020...Last »

March 1, 2016

Similarity of Anti-VEGF Drugs Confirmed For DME Treatment

Posted in: Latest News

A rigorous clinical trial has found that individuals with diabetic macular edema (DME), whose visual acuity is 20/50 or worse, gained more improvement with Eylea than with Avastin. Aside from that, no significant difference was found among the three anti-VEGF drugs (including Lucentis) in subjects with 20/32 or 20/40 vision at the start of treatment. By two years, 41 percent of participants in the
read more »

February 28, 2016

National Eye Institute Receives Funding Increase

Posted in: Latest News

Representatives from Prevent Blindness travel annually to Washington D.C. to advocate for Congressional support of programs and research for the visually impaired. The time spent on Capitol Hill has paid off this year with passage of the Consolidated Appropriations Act of 2016, signed by President Obama in December. Funding has taken some hard hits over
read more »

February 27, 2016

Large Study Shows 1 in 5 People With Vision Loss Experience Hallucinations

Posted in: Eye Conditions, Latest News

A new study conducted by the Canadian National Institute for the Blind (CNIB) has found that one in five Canadians with vision loss who were surveyed experience visual hallucinations, known as Charles Bonnet Syndrome (CBS). The study, titled “Prevalence of visual hallucinations in a national low vision client population”, published in the most recent issue
read more »

February 27, 2016

Future Sustained Drug Delivery Methods for Choroidal Neovascularization

Posted in: Latest News, Research and Developments

During the American Academy of Ophthalmology’s Retina Subspecialty Day in 2015, Peter K. Kaiser, MD, described six alternative methods being looked at for delivery of anti-VEGF drugs into the retinas of individuals experiencing choroidal neovascularization (CNV). Periodic intraocular injections are currently the only procedure for halting damaging blood vessel growth and leakage. Injections are expensive, time-consuming, and burdensome on the patients, so
read more »

February 27, 2016

Low Vision Rehabilitation Needs More Emphasis on Communication and Social Skills

Posted in: Daily Living, Low Vision Rehabilitation

Lea Hyvärinen, MD, PhD (Honorary Professor, Rehabilitation Sciences at Rehabilitation and Education in Blindness or Impairment of Vision in Dortmund, Germany) has described social difficulties caused by types of blindness and visual impairment. In her paper, “Effect of Vision Loss on Communication and Social Skills” she writes that “many problems in communication and social skills are due to misunderstandings
read more »

February 16, 2016

Eye Spy on the App Store

Posted in: Latest News

In collaboration with Prevent Blindness, Regeneron has developed Eye Spy, an app for those with low vision. Download it today! http://ow.ly/YlC5J The Eye Spy app is designed for patients with low vision. The app provides the opportunity for patients and caregivers to learn about their condition and create a community. What You’ll Find In This
read more »

February 15, 2016

New Combination Therapy Treats Retinal Damage in Diabetics

Posted in: Latest News, Research and Developments

Aerpio Therapeutics, Inc. has announced promising results from their “TIME-2” study of  AKB-9778 as a treatment for diabetic retinopathy (DR). AKB-9778 alone and in combination with Lucentis® (ranibizumab) improved underlying retinopathy by 10.0%, and 11.4% compared to 8.8% of patients receiving Lucentis® alone. The clinical findings were presented by Pravin U. Dugel, M.D., at the
read more »

February 10, 2016

AVA-101 May Extend Time Between Wet AMD Treatments

Posted in: Latest News, Research and Developments

In 2014, Avalanche Biotechnologies postulated that a single injection of a new gene therapy treatment could possibly stop blood vessel growth and leakage in the wet form of Age-Related Macular Degeneration (AMD) for several years. A single injection of a drug called AVA-101 (aka sFlt-1) could create a kind of biofactory that continuously secretes a therapeutic protein
read more »

February 5, 2016

High Dose Statins May Be Effective In Treating Dry AMD

Posted in: Latest News, Research and Developments

Researchers at Massachusetts Eye and Ear/Harvard Medical School and the University of Crete have found that high doses of statins (cholesterol-lowering medications) can effectively reduce the number of soft drusen deposits in retinas of people with dry age-related macular degeneration (dAMD). The findings from their phase I/II clinical trial were published in the recent issue of
read more »

February 3, 2016

Accessible Driving Is On The Horizon

Posted in: Latest News, Research and Developments

by Dan Roberts A couple of changes are on the horizon which may allow visually impaired people to regain or maintain the pleasure of piloting their own private vehicles whenever and wherever they choose. The most immediate change could come from relaxation of the minimum visual acuity requirements, made possible in part by the development of bioptic
read more »

February 3, 2016

Bausch + Lomb Partners with Prevent Blindness® to Urge Americans to Fight for Their Sight 

Posted in: Latest News

February is Age-related Macular Degeneration Awareness (AMD) Month From Valentine’s Day to American Heart Health Month, February is traditionally the most heart-driven month of the year. This February, Bausch + Lomb is partnering with Prevent Blindness®, the nation’s oldest volunteer eye health and safety organization, dedicated to fighting blindness and saving sight, to encourage the
read more »

January 27, 2016

New Drug Under Study for Dry MD

Posted in: Latest News, Research and Developments

Ophthotech Corporation has announced that the first patient has been dosed in a Phase 2/3 clinical study of Zimura® (avacincaptad pegol sodium) for treatment of advanced dry macular degeneration (MD).  Zimura® is an inhibitor of complement factor C5, a central component of the complement cascade believed to be involved in the development of AMD. The Company has also recently
read more »

January 25, 2016

Let’s Be Clear About Blue Light

Posted in: Latest News, Research and Developments

Editorial by Dan Roberts The media is becoming saturated with warnings about the so-called “blue light hazard”. Let’s pull it back a bit by being more specific about who should be most concerned. In 2006, I published a paper titled Artificial Lighting and the Blue Light Hazard. The purpose of the paper was to warn of
read more »

January 13, 2016

New Study Underway for Treatment of Dry Macular Degeneration

Posted in: Latest News, Research and Developments

Subjects are being sought for trials to test the new Nova Oculus™ device as the only scientifically supported treatment for dry macular degeneration. Presently, no scientifically proven treatment option is available for those with dry macular degeneration (dMD). Ongoing research, however, is showing that a new device using biocurrent technology (very low micro-current electrical stimulation)
read more »

December 23, 2015

Glaucoma Awareness Can Help Save Your Vision

Posted in: Eye Conditions, Latest News

Important Information from the National Eye Institute Glaucoma is a major cause of vision loss in the U.S. While it currently affects about 3 million Americans, estimates show 6.3 million could have glaucoma by 2050. With Glaucoma Awareness Month in January, it’s a good time to think about scheduling a comprehensive dilated eye exam, especially
read more »

Page 3 of 2712345...1020...Last »

Custom Wordpress design and web development by Jeff Roberts Web Design

WP-Backgrounds by InoPlugs Web Design and Juwelier Schönmann